Retromer Complex

Retromer Complex

Introduction

The retromer complex is a highly conserved multi-protein assembly that mediates the retrograde transport of transmembrane proteins from endosomes back to the trans-Golgi network (TGN) or the plasma membrane. In the central nervous system, retromer dysfunction has emerged as a convergent pathogenic mechanism across multiple neurodegenerative diseases, including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [ALS](/diseases/als), and [FTD](/diseases/ftd). [@mcgough2017]

The retromer plays a critical role in regulating the trafficking of [APP](/genes/app), [BACE1](/proteins/bace1-protein), sortilin, SorLA/SORL1, and neurotransmitter receptors — all proteins whose mislocalization contributes to neurodegeneration. [@seaman2013]

Reduced levels of retromer components, particularly VPS35 and VPS26, are found in the [hippocampus](/brain-regions/hippocampus) and [entorhinal cortex](/brain-regions/cortex) of AD patients, while the VPS35 D620N mutation causes autosomal dominant late-onset [Parkinson's disease](/diseases/parkinsons-disease) — making the retromer both a disease biomarker and a therapeutic target. [@zhang2014]

Structure and Composition

Core Cargo-Recognition Complex

The mammalian retromer core consists of a heterotrimer of vacuolar protein sorting (VPS) proteins:

Retromer Complex

Introduction

The retromer complex is a highly conserved multi-protein assembly that mediates the retrograde transport of transmembrane proteins from endosomes back to the trans-Golgi network (TGN) or the plasma membrane. In the central nervous system, retromer dysfunction has emerged as a convergent pathogenic mechanism across multiple neurodegenerative diseases, including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [ALS](/diseases/als), and [FTD](/diseases/ftd). [@mcgough2017]

The retromer plays a critical role in regulating the trafficking of [APP](/genes/app), [BACE1](/proteins/bace1-protein), sortilin, SorLA/SORL1, and neurotransmitter receptors — all proteins whose mislocalization contributes to neurodegeneration. [@seaman2013]

Reduced levels of retromer components, particularly VPS35 and VPS26, are found in the [hippocampus](/brain-regions/hippocampus) and [entorhinal cortex](/brain-regions/cortex) of AD patients, while the VPS35 D620N mutation causes autosomal dominant late-onset [Parkinson's disease](/diseases/parkinsons-disease) — making the retromer both a disease biomarker and a therapeutic target. [@zhang2014]

Structure and Composition

Core Cargo-Recognition Complex

The mammalian retromer core consists of a heterotrimer of vacuolar protein sorting (VPS) proteins:

| Subunit | Size | Function |
|---------|------|----------|
| VPS35 | 92 kDa | Central scaffold; directly binds cargo sorting receptors (SorLA, sortilin, CI-MPR) and recruits VPS26/VPS29 |
| VPS26 (A or B) | 38 kDa | Binds the N-terminal domain of VPS35; recognizes cargo via aromatic-hydrophobic sorting motifs |
| VPS29 | 21 kDa | Binds the C-terminal domain of VPS35; serves as a regulatory platform for retromer-associated proteins |

VPS35 forms an elongated alpha-helical solenoid that bridges VPS26 (at its N-terminus) and VPS29 (at its C-terminus). Mammalian VPS26 has two paralogues — VPS26A and VPS26B — which form distinct retromer complexes with partially overlapping but non-identical cargo specificity.

Associated Complexes

The cargo-recognition trimer works in concert with:

• Sorting nexins (SNX-BAR): SNX1, SNX2, SNX5, and SNX6 form BAR domain-containing dimers that sense and tubulate endosomal membranes, providing the membrane deformation necessary for retrograde carrier formation
• WASH complex: Recruited to endosomes via VPS35; nucleates Arp2/3-dependent actin polymerization on endosomal membranes, creating actin patches that facilitate cargo sorting and tubule scission
• Retromer-WASH-Arp2/3 axis: Coordinates membrane deformation, actin dynamics, and cargo capture into a single sorting platform

Normal Function in Neurons

Endosome-to-TGN Recycling

The retromer retrieves transmembrane cargo from the limiting membrane of maturing endosomes before they fuse with lysosomes. Key neuronal cargoes include:

• SorLA/SORL1: The sorting receptor for [APP](/genes/app). SorLA diverts [APP](/genes/app) away from [BACE1](/proteins/bace1-protein) in endosomes, reducing [amyloid-beta](/proteins/amyloid-beta) production. Retromer-mediated recycling of SorLA is essential for this protective function. [@fjorback2012]
• Sortilin: Receptor for [progranulin](/proteins/progranulin), [BDNF](/proteins/bdnf), and other neurotrophic factors
• CI-MPR (cation-independent mannose-6-phosphate receptor): Delivers lysosomal enzymes (cathepsins) from TGN to endosomes; its mislocalization impairs lysosomal function

Endosome-to-Plasma Membrane Recycling

The retromer also mediates direct recycling from endosomes to the plasma membrane, particularly important for:

• Glutamate receptors (AMPA, [NMDA receptors](/entities/nmda-receptor)): Maintaining synaptic receptor density and [long-term potentiation](/mechanisms/long-term-potentiation)
• β2-adrenergic receptor: Model cargo for understanding retromer-dependent plasma membrane recycling
• Wntless: Recycling of the Wnt secretion factor, essential for Wnt signaling in the brain

Autophagy Regulation

The retromer regulates [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration) through trafficking of ATG9A, the only multi-spanning transmembrane protein in the core autophagy machinery. Retromer dysfunction mislocalizes ATG9A, impairing autophagosome formation and compromising clearance of protein aggregates — directly linking retromer deficiency to the [protein aggregation](/mechanisms/protein-aggregation) seen in neurodegeneration.

Role in Alzheimer's Disease

Reduced Retromer Levels

Postmortem studies consistently demonstrate reduced levels of VPS35 and VPS26 in the [hippocampus](/brain-regions/hippocampus) and [entorhinal cortex](/brain-regions/entorhinal-cortex) of AD patients. This reduction occurs early in disease — detectable at Braak stage III-IV — suggesting that retromer dysfunction precedes widespread tau pathology and neuronal loss. [@small2015]

APP/BACE1 Trafficking and Aβ Generation

Retromer dysfunction prolongs the co-residence of [APP](/genes/app) and [BACE1](/proteins/bace1-protein) in acidic endosomal compartments — the primary site of amyloidogenic [APP](/genes/app) cleavage. When retromer fails to retrieve [APP](/genes/app), it remains in endosomes where BACE1 cleaves it to produce amyloid-beta, particularly the more aggregation-prone Aβ42. [@muhammad2018]

SORL1 Connection

SORL1 (encoding SorLA) is a confirmed AD risk gene identified through GWAS. SorLA acts as a "gatekeeper" that shunts [APP](/genes/app) away from endosomal BACE1 cleavage. Retromer-mediated recycling of SorLA is essential for maintaining this protective function — reduced retromer directly impairs SorLA recycling, creating a vicious cycle of increasing amyloid-beta production. [@mishra2022] [@knupp2020] [@jensen2023]

SORL1 variants are associated with increased AD risk, and the interaction between SORL1 and retromer dysfunction creates a compounded vulnerability. [@lane2010]

Endosomal Enlargement

One of the earliest neuropathological features in AD — detectable decades before symptom onset in [Down syndrome](/diseases/down-syndrome-alzheimers) patients — is endosomal enlargement in neurons. Retromer dysfunction is a primary driver of this phenotype, as impaired cargo retrieval causes endosomal swelling and disrupted intracellular trafficking.

Tau Phosphorylation Connection

Retromer stabilization in AD models reduces tau phosphorylation independently of amyloid precursor protein processing, suggesting that retromer dysfunction may contribute to tau pathology through distinct pathways. [@young2018]

Role in Parkinson's Disease

VPS35 D620N Mutation

In 2011, the VPS35 D620N missense mutation was identified as a cause of autosomal dominant late-onset [Parkinson's disease](/diseases/parkinsons-disease) (PARK17) — making VPS35 the first endosomal trafficking gene directly linked to PD. [@vilariño2011] [@zimprich2011]

The D620N mutation impairs retromer function through multiple mechanisms:

• Reduced WASH complex recruitment: The mutation weakens VPS35-WASH interaction, impairing endosomal actin dynamics and cargo sorting. [@chen2019]
• Impaired mitophagy: VPS35 D620N disrupts the formation of mitochondria-derived vesicles (MDVs), a retromer-dependent pathway for mitochondrial quality control that operates in parallel with PINK1/Parkin-mediated mitophagy. [@shiraishi2024]
• LRRK2 interaction: The D620N mutation amplifies LRRK2-mediated Rab protein phosphorylation and enhances the LRRK2 response to endolysosomal stress. [@pal2023] [@mccarron2024]
• Alpha-synuclein accumulation: VPS35+/- mice accumulate alpha-synuclein, lose dopaminergic neurons in the [substantia nigra](/brain-regions/substantia-nigra), and show reduced dopamine levels. [@niu2021]
• ATG9A mislocalization: Impaired ATG9A trafficking reduces autophagosome formation, compromising clearance of alpha-synuclein aggregates.

Role in Other Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

Retromer stabilization with the compound 2a (a bis-guanylhydrazone) rescued endosomal sorting, attenuated locomotion impairment, and increased motor neuron survival in ALS mouse models, demonstrating retromer dysfunction as a tractable target in ALS. [@bhatt2020]

Frontotemporal Dementia (FTD)

Retromer dysfunction impairs sorting of [progranulin](/proteins/progranulin) (the product of the GRN gene, a major FTD risk gene), potentially contributing to the lysosomal dysfunction seen in GRN-FTD. [@herrero2021]

Therapeutic Targeting

Pharmacological Retromer Stabilizers

The most promising therapeutic approach is pharmacological chaperone-mediated retromer stabilization — small molecules that bind the VPS35-VPS29 interface to increase retromer complex stability and function:

| Compound | Class | Mechanism | Status |
|----------|-------|-----------|--------|
| R55 | Thiophene thiourea | Binds VPS35-VPS29 interface; increases retromer levels; reduces APP-BACE1 co-localization | Preclinical — reduces amyloid-beta, restores LTP, normalizes synaptic gene expression in AD mice [@bhatt2025] |
| Compound 2a | Bis-guanylhydrazone | Binds VPS35-VPS29; stabilizes retromer; bioavailable | Preclinical — neuroprotective in ALS mouse model [@mcgough2013] |
| RT-011 | — | Retromer stabilizer; increases VPS35 protein levels | Preclinical |

A 2025 study demonstrated that R55 treatment in an AD mouse model rescued synaptic dysfunction, restored endosomal trafficking, reduced amyloid-beta pathology, and normalized the expression of key synaptic genes (Gria1, Grip1, semaphorin/plexin pathway), providing strong preclinical evidence for retromer stabilization as a disease-modifying strategy. [@bhatt2025] [@curtis2023]

The pharmacological chaperone approach was first validated in 2014 with small molecule retromer stabilizers that reduced amyloidogenic APP processing in cell and mouse models. [@mecus2014] Subsequent studies extended these findings to human stem cell models of AD. [@young2018]

Gene Therapy Approaches

AAV-mediated overexpression of VPS35 has been explored as a gene therapy strategy for PD. In VPS35+/- mice, VPS35 restoration prevents dopaminergic neurodegeneration and normalizes alpha-synuclein levels.

Clinical Development

A 2024 review discusses the progress in developing retromer-targeting therapeutics, highlighting the challenges of targeting a non-enzymatic scaffold protein and the promise of pharmacological stabilization approaches. [@wu2024] The field has advanced from proof-of-concept in cellular models to demonstrated efficacy in multiple animal models of AD, PD, and ALS.

External Links

• [VPS35 — NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/55737)
• [VPS26A — UniProt (O75436)](https://www.uniprot.org/uniprot/O75436)
• [VPS35 — OMIM (601501)](https://omim.org/entry/601501)
• [Retromer Complex — Reactome](https://reactome.org/content/detail/R-HSA-8868766)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Retromer Complex discovered through SciDEX knowledge graph analysis: